Home / Business and Economy / Zealand Pharma, Generate Biomedicines Forge $1.2B AI Deal
Zealand Pharma, Generate Biomedicines Forge $1.2B AI Deal
14 Oct
Summary
- Two companies partnered using AI to create protein-based treatments.
- The collaboration focuses on obesity and other metabolic diseases.
- The deal is potentially worth nearly $1.2 billion in milestones.
A significant collaboration has been formed between Zealand Pharma and Generate Biomedicines, aiming to revolutionize the treatment landscape for obesity and metabolic disorders. This partnership harnesses the power of artificial intelligence to pioneer new protein-based therapies.
The agreement includes an initial $30 million payment to Generate Biomedicines, with further potential for up to $35 million in early preclinical milestones. The total value of the deal could reach nearly $1.2 billion, contingent upon the successful development, regulatory approval, and commercialization of the targeted treatments.
Under the terms of the collaboration, Generate Biomedicines will spearhead the research phase, focusing on identifying promising lead candidates. Subsequently, Zealand Pharma will assume responsibility for the critical stages of clinical development, navigating regulatory submissions, and overseeing the global commercialization efforts for the resulting therapies.
